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Abstract To identify proteins that interact with Huntingtin-
interacting protein-2 (Hip-2), a ubiquitin-conjugating enzyme, a
yeast two-hybrid screen system was used to isolate five positive
clones. Sequence analyses showed that, with one exception, all
Hip-2-interacting proteins contained the RING finger motifs.
The interaction of Hip-2 with RNF2, one of the clones, was
further confirmed through in vitro and in vivo experiments.
Mutations in the RING domain of RNF2 prevented the clone
from binding to Hip-2, an indication that the RING domain is the
binding determinant. RNF2 showed a ubiquitin ligase (E3)
activity in the presence of Hip-2, suggesting that a subset of
RING finger proteins may have roles as E3s. ß 2001 Published
by Elsevier Science B.V. on behalf of the Federation of Euro-
pean Biochemical Societies.
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1. Introduction
Ubiquitin-dependent proteolytic system is a major pathway
involved in the eukaryotic cells for selective protein degrada-
tion. The ubiquitination pathway generally involves three
classes of enzymes, including a ubiquitin-activating enzyme
(E1), a ubiquitin-conjugating enzyme (E2), and a ubiquitin
ligase (E3) [1,2]. Ubiquitin is ¢rst activated by E1 through a
thiolester bond between the C-terminal glycine of ubiquitin
and a cysteine residue of E1, and is then transferred into an
E2 cysteine residue. E2 by itself, or in concert with E3, cata-
lyzes the formation of an isopeptide bond between the C-ter-
minal glycine of ubiquitin and the O-amino group of lysine
residues on the target proteins. The ubiquitinated proteins
are then ¢nally recognized and degraded by the 26S protea-
some complex [3].
A large number of E2s exist; for example, in yeast, at least
10 di¡erent E2s have been identi¢ed, whereas, in Arabidopsis
thaliana, more than 30 are present, and over 20 have been
detected in mammalians [4^6]. Functions of these enzymes
include roles in DNA repair, cell cycle progression, organelle
biogenesis, secretion, and stress response. All known E2s con-
tain the UBC domain, a conserved core domain of approx-
imately 150 amino acids in size, and are classi¢ed into four
groups by the presence of additional N-terminal and/or C-ter-
minal amino acid sequences [4].
Huntingtin-interacting protein-2 (Hip-2) is homologous to a
human ubiquitin-conjugating enzyme E2^25K. This protein
has similarities to the UBC-1, -4, and -5 enzymes of Saccha-
romyces cerevisiae. In addition, it is highly expressed in the
cortex and striatum in brain regions of Huntington’s patients
and interacts speci¢cally with the N-terminus of huntingtin,
implying that the cellular level of huntingtin is normally regu-
lated in part by the ubiquitin-dependent degradation [7].
Recent studies reported that certain ubiquitin-conjugating
enzymes interact with the RING ¢nger proteins that may play
roles as E3s in the ubiquitin^proteosome-dependent pathway
[8^14]. In this study, we identi¢ed several RING ¢nger pro-
teins that interact with Hip-2 through the yeast two-hybrid
system. We provide direct evidence that the RING ¢nger do-
main is responsible for the interaction and is crucial for E3
activities of the proteins.
2. Materials and methods
2.1. Yeast two-hybrid screening and L-galactosidase assay
LexA yeast two-hybrid system (Clontech) was applied to identify
the intracellular proteins capable of binding to Hip-2 from a human
fetal brain cDNA library. A full-length Hip-2 was ampli¢ed through
the polymerase chain reaction (PCR) with Pfu polymerase (Strata-
gene) and was then cloned into pLexA. The yeast two-hybrid screen
was performed following the manufacturer’s instructions (Clontech).
Positive clones were further characterized by sequencing and were
searched for possible gene homologies through the NCBI GenBank
BLAST and BCM (Baylor College of Medicine) search.
Liquid L-galactosidase activity assays were performed to quantify
the strength of interaction for protein pairs using o-nitrophenyl L-D-
galactopyranoside (ONPG) as a substrate according to the manufac-
turer’s instructions (Clontech).
2.2. Construction of truncate and mutant plasmids
RNF2vC1 (RNF1ÿ93) was generated by the digestion of a full-
length RNF2 with EcoRI and SpeI, and was cloned into pB42AD.
RNF2vC2 (RNF1ÿ156) and RNF2vN1 (RNF180ÿ337) were constructed
by digesting a full-length RNF2 with EcoRI and PstI, and with PstI
and XhoI, respectively. The resulting products were then ampli¢ed
through PCR using primers, which contained EcoRI and XhoI sites
on the N-terminal and the C-terminal regions, respectively. The am-
pli¢ed PCR products were digested with EcoRI and XhoI and inserted
into pB42AD.
The constructs of C51W/C54S (cysteine to tryptophan at the amino
acid 51 and cysteine to serine at the amino acid 54) and H69Y (his-
tidine to tyrosine at the amino acid 69) mutants were generated using
a Quickchange site-directed mutagenesis kit (Stratagene) and speci¢c
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oligonucleotides. All constructs were con¢rmed by sequencing the
mutated regions. The mutants were cloned into pB42AD and used
in the yeast two-hybrid system and L-galactosidase assay.
2.3. In vitro binding assays
A full-length RNF2 was cloned into pGEX4T-1 to generate a GST^
RNF2 fusion protein (Pharmacia Biotech, Uppsala, Sweden). 35S-la-
beled Hip-2 was generated with the TNT-coupled reticulocyte lysate
system following the manufacturer’s instructions (Promega).
2.4. In vivo binding assays by co-precipitation experiments
For co-precipitation experiments, Hip-2 containing an N-terminal
GST-epitope tag was transiently co-transfected with Xpress epitope-
tagged RNF2 into COS7 cells. GST pull down assay was performed
as described previously [15]. Anti-GST antibody (Ab) and anti-Xpress
Ab were purchased from Amersham Pharmacia (1:3000 diluted) and
Invitrogen (1:3000 diluted), respectively.
2.5. In vitro ubiquitination assay
The experiment was carried out according to a previously published
report [10] with modi¢cations. GST^RNF2 immobilized to the gluta-
thione^Sepharose beads was combined with 20 ng of E1, 20 ng of E2,
and 10 Wg of ubiquitin (Sigma) in a ubiquitination bu¡er (50 mM
Tris^HCl (pH 7.4), 2 mM ATP, 5 mM MgCl2, 2 mM DTT, 1 mM
creatine phosphate, 15 units of creatine phosphokinase and BL-21 cell
lysates) and the mixture was incubated for 1.5 h at 30‡C. The reac-
tions were terminated by adding a stop bu¡er (SDS sample bu¡er
containing L-mercaptoethanol) and processed for 10% SDS^PAGE.
Western blotting experiments were performed using the anti-ubiquitin
Ab.
3. Results and discussion
3.1. Hip-2 interacts with a family of RING ¢nger proteins
To identify the proteins that interact with Hip-2, we per-
formed a yeast two-hybrid screen. Yeasts expressing the full-
length LexA^Hip-2 protein were transformed with a human
brain cDNA library. Five positive clones were identi¢ed by
screening approximately 2.1U107 Trp, Leu auxotrophic
transformants. Database searches performed at NCBI using
the BLASTX program revealed that, with one exception, all
Hip-2-interacting clones contained the RING ¢nger motifs.
Hip-2-interacting protein-1, termed HIPI-1, showed 97% iden-
tity to the Homo sapiens HSD-4 mRNA (accession number
AF162680). In addition, HIPI-3 and HIPI-4 were 100% iden-
tical to the H. sapiens RNF2/dinG/RING1b mRNA (acces-
sion number Y10571) and RNF24 (accession number
XM009564), respectively, while HIPI-8 was revealed to be a
novel RING ¢nger gene. On the other hand, HIPI-6, the one
exception that did not contain the RING ¢nger motif, was
99% identical to the H. sapiens HSPC035 mRNA (accession
number AF078855.1).
Comparisons of the amino acid sequences among HIPIs
revealed no signi¢cant homologies in the structures except
that all proteins contained the RING domain sequences
(Fig. 1). RNF2, HIPI-8, and HSD-4 belong to the RING-
HC (C3HC4)-type and, interestingly, have 12 amino acid se-
quences between Cys2 and Cys3 (Fig. 1). On the other hand,
RNF24 belongs to the RING-H2 (C3H2C3)-type and has 14
amino acid residues between Cys2 and Cys3. One common
characteristics of HIPIs that contain the RING ¢nger do-
mains, as compared to other RING proteins, is that a phenyl-
alanine (F) residue exists in front of the Cys4 position. Re-
cently, ubcM4, a ubiquitin-conjugating enzyme, was revealed
to interact with the RING ¢nger proteins, termed UIPs
(ubcM4-interacting proteins) [8]. Though all UIPs belong to
the RING-HC (C3HC4)-type, they possess more amino acid
residues between Cys5 and Cy6 than HIPIs.
3.2. Interaction of RNF2 in vitro and in vivo with Hip-2
In order to con¢rm the interaction between Hip-2 and
RNF2 (HIPI-3), in vitro binding assays were performed using
GST fusion proteins. 35S-Radiolabeled Hip-2s were generated
using the rabbit reticulocyte lysates and assessed for their
capability to form a stable complex with the GST^RNF2
protein or GST alone, a negative control. Hip-2 was shown
to e⁄ciently bind to GST^RNF2, but not to GST alone (Fig.
2A).
To further verify whether RNF2 interacts with Hip-2 in
mammalian cells, in vivo binding assays were performed.
COS-7 cells were harvested 48 h after co-transfection with
pcDNA3.1/Xpress-RNF2 and pcDNA3.0/GST^Hip-2. The
transfected cell extracts were mixed with glutathione^Sephar-
ose beads, and proteins that were bound to the GST^Hip-2
coupled with the beads were then probed with an anti-Xpress
Ab to detect the RNF2 protein. Results revealed that RNF2
proteins were bound to the GST^Hip-2 fusion proteins (Fig.
2B)., while no interaction was observed between RNF2s and
GST proteins (data not shown). These results suggest that
RNF2 binds to Hip-2 under in vivo conditions and, further-
more, con¢rm the interaction detected through the yeast two-
hybrid assays.
3.3. The RING ¢nger domain in RNF2 is essential for the
recognition of Hip-2
To de¢ne the protein region responsible for the interaction
between RNF2 and Hip-2, deleted versions of RNF2 were
expressed as LexA^BD fusion proteins in yeasts. LacZ report-
er gene was activated in cells coexpressing LexA^Hip-2 and
pB42AD full-length RNF2, -RNF2vC1 or -RNF2vC2 (Fig.
3A,B). However, no detectable L-galactosidase activity was
observed in cells expressing the protein pair LexA^Hip-2
and pB42AD^RNF2 C-terminal stretch (aa 180^337). These
results indicate that the N-terminal region of RNF2, including
the RING ¢nger domain, is essential for the observed pro-
tein^protein interaction.
To further verify the role of the RING domain as the Hip-2-
Fig. 1. RING ¢nger motifs of Hip-2-interacting proteins. A comparison of the ring ¢nger structure of HIPIs is shown. Cysteine residues are
numbered. The conserved cysteine and histidine residues of the RING ¢nger motif are marked with asterisks. White letters on the dark back-
ground and dark letters on the gray background indicate residues that are conserved in at least 80 and 50^80% of the aligned sequences, re-
spectively.
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interacting region, we generated the following two missense
mutations in the domain, which disrupt the RING structure:
C51W/C54S (cysteine to tryptophan at the amino acid 51 and
cysteine to serine at the amino acid 54) and H69Y (histidine
to tyrosine at the amino acid 69). Yeast two-hybrid and
L-galactosidase assays revealed a very weak L-galactosidase
activity in the double mutant C51W/C54S, and no activity
in the single mutant H69Y (Fig. 3A,B). In control experiments
performed to verify our results, coexpression of pB42AD^
RNF2 and LexABD-atropine-1 (DRPLA gene) as a negative
control showed no L-galactosidase activity (data not shown).
Taken together, these data indicate that the RING ¢nger
domain in RNF2 has a critical role in the recognition of
Hip-2 ubiquitin-conjugating enzyme.
3.4. RNF2 plays a role as an E2-dependent ubiquitin ligase
Recently, several proteins containing the RING ¢nger do-
main revealed to be E3 ubiquitin ligases (reviewed in [16^19]).
Therefore, we performed in vitro ubiquitination assays to as-
sess whether RNF2 has an E2-dependent E3 activity. A ubiq-
uitination pattern was observed in the presence of E1, Hip-2,
and RNF2 (lane 5 in Fig. 4A), whereas none was detected in
the absence of RNF2 (lane 4 in Fig. 4A), which suggests that
RNF2 functions as E3. A mixture of E1, ubcH5b, and AO7,
as a positive control, generated high molecular weight-
smeared bands indicative of polyubiquitination (lane 2 in
Fig. 4A). Similar results were obtained using 32P-labeled ubiq-
uitin (data not shown).
To verify that the RING ¢nger domain is important for the
E3 activity, we used the deleted or mutant RNF2 proteins
instead of the wild-type in the ubiquitination assays. Ubiqui-
tinated proteins were only detected in the presence of the wild-
type RNF2 (lane 2 in Fig. 4B), indicating that RNF2 has an
E3 activity in a RING-dependent manner and exhibits a
RING-type E3 ligase activity through the interaction with
Hip-2 in an E2-dependent manner.
3.5. RNF2 can be paired with closely related ubc4 and ubcH5b
in the ubiquitination pathway
Although E2s have a common biological feature of ubiqui-
tin conjugation, all E2s appear to possess their respective cog-
nate E3s. We investigated whether RNF2 has a speci¢c inter-
action with other E2s. ubc4, ubcH5b, ubcH6, and ubcH9
proteins, which were expressed in Escherichia coli and puri¢ed
using a glutathione a⁄nity column, were assayed in the pres-
ence of mammalian E1, ubiquitin, and an ATP-regenerating
system. High molecular-ubiquitinated bands were observed
only in the presence of the Hip-2-related proteins, ubc4 and
ubcH5b (Fig. 4C), but not in the unrelated proteins, ubcH6
and ubcH9, indicating that RING ¢nger proteins functioning
as E3s interact with speci¢c E2s. These results imply that
RING proteins may contribute to the substrate speci¢city in
the degradation of proteins through a ubiquitin-dependent
pathway.
The diversity and the number of proteins that are regulated
by the ubiquitination foretell the existence of a large number
of E3s. However, to date, relatively few E3s have been found.
In this study, we identi¢ed several RING ¢nger proteins that
Fig. 2. Hip-2 interacts with RNF2 in vitro and in vivo. A: 35S-ra-
diolabeled Hip-2s were generated using rabbit reticulocyte lysates
and assessed for their capability to form a stable complex with
GST^RNF2 protein or GST alone. B: Co-precipitation of the
RNF2 protein with Hip-2. GST-tagged-Hip-2 and Xpress-tagged-
RNF2 were transiently transfected into COS-7 cells. After 48 h, the
cells were harvested, and Western blotting experiments were per-
formed. Detections were made using an anti-Xpress Ab (1:3000),
and the blot was stripped to reprobe with an anti-GST Ab
(1:3000).
Fig. 3. RING domain of RNF2 is necessary for the interaction with
Hip-2. A: Schematic representation of wild-type RNF2 and various
mutant constructs. The interaction with Hip-2 was determined using
the yeast two-hybrid assays (right). The RING ¢nger domain is in-
dicated with striped bars. B: The strength of interaction with Hip-2
was measured using the L-galactosidase assays. Lane 1, BD/empty-
AD/TAg; lane 2, BD/p53-AD/TAg; lane 3, BD/Hip-2^AD/
RNF2vC1; lane 4, BD/Hip-2^AD/RNF2vC2; lane 5, BD/Hip-2^
AD/RNF2vN1; lane 6, BD/Hip-2^AD/RNF2 (wt); lane 7, BD/Hip-
2^AD/RNF2 (C51W/C54S); lane 8, BD/Hip-2^AD/RNF2 (H69Y).
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interact with an E2 enzyme, Hip-2 (hE2^25K), and found
evidence that RNF2 has a role as an E3 ligase, which suggest
that other proteins identi¢ed through the yeast two-hybrid
screen may also function as E3 ligases. We generated various
truncates and missense mutations in the RING ¢nger domain
of RNF2 protein. Both the yeast two-hybrid assays and
L-galactosidase experiments showed that mutant forms of
the RING domain lost their ability to bind to Hip-2 (Fig. 3).
In addition, the mutants did not act as E3s in the ubiquitina-
tion assays (Fig. 4). Thus, the RING ¢nger domain of RNF2
is not only required for interacting with Hip-2 but also for
acting as an E3 ligase. These studies would expand the pool of
E3 ligases and provide information of speci¢city on the ubiq-
uitination-related proteins for determining the ubiquitination
target substrates.
RNF2/dinG/RING1B is a homolog of the human RING1
protein. RING1A and RING1B were recently shown to in-
teract with other mammalian PcG proteins and were identi¢ed
as new members of the Pc group family [20^23]. Ring1A has
been known to behave as a transcriptional repressor, whereas
the function of RNF2/Ring1B protein has not yet been re-
vealed. Our study demonstrates that RNF2 has a role as an
E3 ligase, providing an insight into the new function of the
RNF2/dinG/RING1B protein.
Abnormal ubiquitinations have been found at increased
levels in neuropathological diseases including Alzheimer’s dis-
ease and Parkinson’s disease, suggesting that the ubiquitina-
tion is common pathological pathway among neurodegenera-
tive disorders. Thus, an abnormal ubiquitination pathway
may be related to HD in which Hip-2 and RNF2 may have
a role as important ubiquitination components in HD. These
studies may lead to novel diagnostic and therapeutic ap-
proaches to HD.
Acknowledgements: We thank Dr. Jensen (NIH, Bethesda, MD,
USA) for providing the ubiquitin assay system. This work was sup-
ported in part by Grants from the Korea Health 21 RpD project,
Ministry of Health and Welfare, Republic of Korea (HMP-00-B-
21300-00202) and the Korea research Foundation (00-B-21300-0072).
References
[1] Finley, D. and Chau, V. (1991) Annu. Rev. Cell. Biol. 7, 25^69.
[2] Hershko, A., Ciechanover, A. and Varshavsky, A. (2000) Nat.
Med. 6, 1073^1081.
[3] Hochstrasser, M. (1996) Cell 84, 813^815.
[4] Jentsch, S. (1992) Annu. Rev. Genet. 26, 179^207.
[5] Girod, P.A. and Vierstra, R.D. (1993) J. Biol. Chem. 268, 955^
960.
[6] Joazeiro, C.A. and Weissman, A.M. (2000) Cell 102, 549^552.
[7] Kalchman, M.A. et al. (1996) J. Biol. Chem. 271, 19385^19394.
[8] Martinez-Noel, G., Niedenthal, R., Tamura, T. and Harbers, K.
(1999) FEBS Lett. 454, 257^261.
[9] Moynihan, T.P., Ardley, H.C., Nuber, U., Rose, S.A., Jones,
P.F., Markham, A.F., Sche¡ner, M. and Robinson, P.A. (1999)
J. Biol. Chem. 274, 30963^30968.
[10] Lorick, K.L., Jensen, J.P., Fang, S., Ong, A.M., Hatakeyama, S.
and Weissman, A.M. (1999) Proc. Natl. Acad. Sci. USA 96,
11364^11369.
[11] Joazeiro, C.A., Wing, S.S., Huang, H., Leverson, J.D., Hunter,
T. and Liu, Y.C. (1999) Science 286, 309^312.
[12] Leverson, J.D., Joazeiro, C.A., Page, A.M., Huang, H., Hieter,
P. and Hunter, T. (2000) Mol. Biol. Cell 11, 2315^2325.
[13] Xie, Y. and Varshavsky, A. (1999) EMBO J. 18, 6832^6844.
[14] Fang, S., Jensen, J.P., Ludwig, R.L., Vousden, K.H. and Weiss-
man, A.M. (2000) J. Biol. Chem. 275, 8945^8951.
[15] Rhim, H., Bok, K.-S., Chang, M.-J., Kim, I.-K., Park, S.S. and
Kang, S. (1998) J. Microbiol. Biotechnol. 8, 663^668.
[16] Freemont, P.S. (2000) Curr. Biol. 10, R84^R87.
[17] Tyers, M. and Jorgensen, P. (2000) Curr. Opin. Genet. Dev. 10,
54^64.
[18] Jackson, P.K., Eldridge, A.G., Freed, E., Furstenthal, L., Hsu,
J.Y., Kaiser, B.K. and Reimann, J.D. (2000) Trends Cell. Biol.
10, 429^439.
[19] Claudio, A.P., Joazeiro, C.A. and Hunter, T. (2000) Science 289,
2061^2062.
[20] Schoorlemmer, J., Marcos-Gutierrez, C., Were, F., Martinez, R.,
Garcia, E., Satijn, D.P., Otte, A.P. and Vidal, M. (1997) EMBO
J. 16, 5930^5942.
[21] Hemenway, C.S., Halligan, B.W. and Levy, L.S. (1998) Onco-
gene 16, 2541^2547.
[22] Hemenway, C.S., Halligan, B.W., Gould, G.C. and Levy, L.S.
(2000) Gene 242, 31^40.
[23] Atsuta, T., Fujimura, S., Moriya, H., Vidal, M., Akasaka, T. and
Koseki, H. (2001) Hybridoma 20, 43^46.
Fig. 4. RNF2 is involved in the E2-dependent ubiquitination in vi-
tro. A: GST^RNF2 fusion protein was incubated with or without
E1 and E2, and ubiquitination patterns were investigated using a
ubiquitin Ab. The ubcH5b and AO7 are positive controls, and Omi/
HtrA2 is a negative control. B: GST-fused mutants were evaluated
for the ubiquitination activity (upper panel). In the lower panel,
anti-GST antibodies were used to con¢rm the expression of the fu-
sion proteins, which are indicated with asterisks. C: Glutathione
bead-immobilized E2s were incubated with mammalian E1 and
RNF2. The experiments were performed as described in Section 2.
RNF2 exhibits ubiquitin ligase activity in the presence of ubc4 and
ubcH5b, but not with ubcH6 and ubcH9.
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